Kyn Therapeutics Banks $49M to Advance Cancer Immunometabolism Therapies Post author:Sam Post published:December 13, 2017 Post category:BioPharma Investors were Atlas Venture and OrbiMed. Source: BioSpace You Might Also Like Norwegian Biotech Upstart Has Become a Potential Takeover Target February 19, 2017 Deal Spree Continues as Allergan Inks $2.47 Billion Deal for This Bay Area Biotech February 12, 2017 Axovant's Nightmare Week Continues After CEO Admits Numbers Were Even Worse Than Reported Yesterday January 8, 2018
Axovant's Nightmare Week Continues After CEO Admits Numbers Were Even Worse Than Reported Yesterday January 8, 2018
